Pure red-cell aplasia associated with pegylated interferon-alpha-2b plus ribavirin

American Journal of Hematology

Volumn 83, Issue 9, 2008, Pages 758-759

  Miura, Yuji ^a   Kami, Masahiro ^b   Yotsuya, Ron ^a   Toda, Nobuo ^a   Komatsu, Tsunehiko ^a  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METENOLONE ACETATE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; CASE REPORT; CHRONIC HEPATITIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROCYTE APLASIA; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HEPATITIS C; HUMAN; LETTER; MALE; PRIORITY JOURNAL; RETICULOCYTE COUNT; SIDE EFFECT; TREATMENT OUTCOME; VIRUS HEPATITIS;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RED-CELL APLASIA, PURE; RIBAVIRIN;

EID: 51449097460     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21229     Document Type: Letter

References (5)

1. Tanaka N, Ishida F, Tanaka E. Ribavirin-induced pure red-cell aplasia during treatment of chronic hepatitis C. N Engl J Med 2004;350:1264-1265.
2. Hirri HM, Green PJ. Pure red cell aplasia in a patient with chronic granulocytic leukaemia treated with interferon-alpha. Clin Lab Haematol 2000;22:53-54.
3. Tomita N, Motomura S, Ishigatsubo Y. Interferon-alpha-induced pure red cell aplasia following chronic myelogenous leukemia. Anticancer Drugs 2001;12:7-8.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-965.